Shares of Pro Medicus Ltd (ASX: PME) plummeted 5.86% in Friday's trading session, as growth stocks continue to face selling pressure in the market. The sharp decline comes amid a broader correction affecting high-flying growth names across various sectors.
The selloff in Pro Medicus aligns with a trend observed in other quality growth stocks, which have shed 10% to 30% in recent weeks. Market experts suggest that while such corrections can be unsettling for investors, it's crucial to stay focused on company fundamentals rather than making emotional decisions based solely on price movements.
Despite the current downturn, some investors see potential opportunities in Pro Medicus. Adam Dawes, Senior Investment Adviser at Shaw & Partners, noted, "We took advantage of weakness in Pro Medicus – longer term, the global imaging opportunity remains intact." This perspective highlights the importance of maintaining a long-term view on high-quality growth companies, even during periods of market volatility.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。